{
  "abstract": "Introduction Systemic sclerosis (SSc) is frequently complicated with interstitial lung disease (ILD) as a major contributing cause of both mortality and disability. Approximately 65-85% of patients with SSc develop ILD (SSc-ILD) of varibgle severity and 25-30% develop aggressive disease than is associated with the significant mortality of 40% over a 10-year period. Lung involvement Results in an estimated 35% of all SSc-related deaths. The cytokines, interleukins and chemokines are often elevated in SSc. IL-1, IL-4, IL6, IL-10, IL-13 and others have all been reported to be elevated in SSc.Our aim was to test change of IL-13 in patients with SSc and various patterns of interstitial lung disease (SSc-ILD). The role of IL-13 relevant to specific organ system disease in SSc would be discussed.Material and Methods Serum levels of IL-13 were examied by ELISA and measured in 62 patients with SSc-ILD at two points (mean age atenrollment was 49.5 ± 13.1, fem 49 (79%), with diffuse form 64,5%, the average follow-up duration was18.7 ±14 months). All of the patients underwent HRCT on 1.0-1.5 mm thick overlapping sections using a high-spatial-frequency reconstruction algorithm, which were taken during a single breath hold using various computed tomography scanners. The HRCT images were evaluated byexperienced radiologist. HRCT patterns were presence of reticulations, honeycombing, ground-glass opacity.Results Mean dates of serum level of IL-13 were 5.74 ± 25.12, med 0,001 [0.001;0.01] and 2.0 ± 8.82, med 0,001 [0.001;0.001].Serum level of IL-13 at the first point correlated with level of TGF-b at the second point (R=0.292 (p<0.05)) and was significantly decreased with reticulations (p=0.04), ground-glass opacity (p=0,04) and tended to decrease without honey combing (p=0.064).We also found a negative correlation level of IL-13 with total dose of cyclophosphamide (R=-0.248 (p<0.05)).Conclusions Our dates indirectly confirm that IL-13 indirectly induces fibrosis by activating macrophages that produce TGF-b. A molecular understanding of pathogenic pathways is expected to lead to the development of novel therapeutic strategies aimed at targeting these cells and the pathways governing abnormal expression of the cytokines they produce.",
  "authors": [
    {
      "affiliations": [
        "V.A. Nasonova Reserch Institute of Rheumatology, Moscow, Russia"
      ],
      "name": "Olga Ovsyannikova"
    },
    {
      "affiliations": [
        "V.A. Nasonova Reserch Institute of Rheumatology, Moscow, Russia"
      ],
      "name": "Olga Koneva"
    },
    {
      "affiliations": [
        "V.A. Nasonova Reserch Institute of Rheumatology, Moscow, Russia"
      ],
      "name": "Liudmila Garzanova"
    },
    {
      "affiliations": [
        "V.A. Nasonova Reserch Institute of Rheumatology, Moscow, Russia"
      ],
      "name": "Rushana Shayachmetova"
    },
    {
      "affiliations": [
        "V.A. Nasonova Reserch Institute of Rheumatology, Moscow, Russia"
      ],
      "name": "Lidiya Ananyeva"
    },
    {
      "affiliations": [
        "V.A. Nasonova Reserch Institute of Rheumatology, Moscow, Russia"
      ],
      "name": "Anastaia Avdeeva"
    },
    {
      "affiliations": [
        "V.A. Nasonova Reserch Institute of Rheumatology, Moscow, Russia"
      ],
      "name": "Michail Diatroptov"
    }
  ],
  "title": "P.093 Association TH serum level of IL-13 with interstitial lung disease in systemic sclerosis patients",
  "uid": "2be4c0b8-fa13-5c5f-9432-175548760f4f"
}